Actionable insights straight to your inbox


Ocular Therapeutix (OCUL) Doses First Patient in Phase 1 Macular Degeneration Trial

OCUL testing tyrosine kinase inhibitor implant for wet age-related macular degeneration (AMD)
Ocular Therapeutix ($OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary
Full IPO calendar & reports HERE. The follow list is in order of largest IPO first.  (1) Based in Luxembourg, Orion Engineered Carbons S.a r.l. (OEC) scheduled a $315 million IPO on